The South African TB Vaccine Initiative (SATVI), based at the University of Cape Town is a co-research site in the ongoing phase II VPM1002 infant trial. SATVI is a tuberculosis (TB) research group with a research scope that spans several disciplines including paediatrics, infectious diseases, epidemiology, public health, immunology, systems biology and clinical sciences. Their research focus is understanding the risk for, and protection against, M. tuberculosis infection and TB disease, in order to develop more effective vaccines and preventive strategies. Clinical trials are conducted in phases amongst small groups of people in the early phases (phases I and II) and amongst larger groups of people once safety has been determined (phases III and IV). In the proposed phase III trial they will extend their work and contribute to this trial.